Guselkumab Dose 2
Guselkumab Dose 2 is a pharmaceutical drug with 8 clinical trials. Currently 3 active trials ongoing. Historical success rate of 80.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
5
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
80.0%
4 of 5 finished
20.0%
1 ended early
3
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
A Study of Guselkumab in Participants With Systemic Sclerosis
A Study of Guselkumab in Participants With Active Lupus Nephritis
Clinical Trials (8)
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
A Study of Guselkumab in Participants With Systemic Sclerosis
A Study of Guselkumab in Participants With Active Lupus Nephritis
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8